By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...
Emraclidine was the main reason AbbVie acquired Cerevel for $8.7 billion, and I expect a substantial impairment charge on ...
AbbVie added emraclidine via the approximately $8.7 billion acquisition of Cerevel Therapeutics. Last year, an analyst ...
AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed ...
AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...
The transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging ...
EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell ...
The Big Pharma is also looking to the remaining pipeline from the Cerevel deal. Tavapadon, for example, recently met the ...
The readout makes AbbVie's wager on Cerevel, which came ahead of key data readouts, look like a poor deal. The company said ...
This morning, pharma major AbbVie and fellow USA-based EvolveImmune Therapeutics announced the signing of a collaboration and ...
U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...
The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback